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Abstract. T cells are key players in the immune action against the invasion of can-
cer cells. During an immune response, antigen-specific T cells dynamically sculpt the
antigenic distribution of cancer cells, and cancer cells concurrently shape the repertoire
of antigen-specific T cells. The succession of these reciprocal selective sweeps can re-
sult in “chase-and-escape” dynamics, and lead to immune evasion. It has been proposed
that immune evasion can be countered by immunotherapy strategies aimed at regulating
the immune response. In this work, we present a mathematical model of the compe-
tition between cancer cells and T cells under immunotherapy. We show that effective
immunotherapy protocols can be designed by using therapeutic agents that boost T-cell
proliferation in combination with boosters of immune memory.
1 Introduction
Antigen-specific T cells and cancer cells can be viewed as predator and prey populations that are
engaged in a continuous tussle, see for instance [4] and [10]. To catch cancer cells, T cells need to
be efficient hunters. On the other hand, cancer cells must be able to escape predation by antigen-
specific T cells, if enough of them are to survive and colonise host tissues. Immunotherapy is a type
of treatment that can be used to boost or restore the ability of the immune system to fight cancer,
infections and other form of disease. Currently there is evidence that immunotherapies are one of
the most promising weapon in the tumor fight, however still research should be addressed to achieve
durable clinical improvements, see for instance [1].
To explore these ideas, here we introduce a mathematical model of selection dynamics in a well-
mixed sample of antigen-specific T cells and cancer cells, under the action of two hypothetical classes
of therapeutic agents designed to: stimulate antigen-independent proliferation (P-agents); interfere
with homeostasis to reduce the death rate of antigen-specific T cells (M-agents).
We employ an integro-differential formalism, see for instance [8], where the T-cell and cancer-cell
populations are structured by their target-antigenic and antigenic expression, respectively. Analogous
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models have previously been used to study, for instance, cancer immunoediting [3] and the emergence
of anti-cancer drug resistance [6].
2 Model and results
We consider an integro-differential model of selection dynamics in a well-mixed sample of cancer
cells and antigen-specific T cells. Cancer cells proliferate and die due to competition for limited re-
sources, T cells undergo antigen-dependent proliferation, and T-cell numbers are kept under control by
homeostatic regulation mechanisms that induce cell death. The interaction between antigen-specific
T cells and their targets result in a selective action against cancer cells. Furthermore, two hypothetical
classes of therapeutic agents are considered, which are designed to stimulate antigen-independent ex-
pansion (P-agents) and interfere with homeostasis to reduce the death rate of antigen-specific T cells
(M-agents).
We use a continuous real variable u ∈ U ⊂ R to model the antigenic expression of cancer cells, and
a continuous real variable v ∈ V ⊆ U to describe the target antigenic expression of antigen-specific
T cells. The function nC(t, u) ≥ 0 represents the density of cancer cells with antigenic expression u
at the time instant t > 0 (i.e. the population density of cancer cells), while the function nT (t, v) ≥ 0
identifies the density of T cells that are targeted to cancer cells with antigenic expression v (i.e. the
population density of T cells). The global population densities of cancer cells and T cells, ρT and ρC ,
are computed as integrals of the population densities of T cells and cancer cells.
With assumptions similar to those presented in [2] and [5], we describe the dynamics of the two
cell populations through the following system of integro-differential equations:
∂
∂t
nC(t, u) = nC(t, u)
(
κC − μC
∫
U
nC(t, u)du
)
︸︷︷︸
proliferation of cancer cells and competition for resources
− βS nC(t, u)
∫
V
e−
(u−v)2
θ nI(t, v)dv︸︷︷︸
T-cell action against cancer cells
,
∂
∂t
nI(t, v) = nI(t, v)
[
βE
∫
U
e−
(u−v)2
θ nC(t, u)du + κPcP(t)
]
︸︷︷︸
clonal expansion and boosting of T-cell proliferation
− μI
1 + μMcM(t)
nI(t, v)
∫
U
nI(t, v)dv︸︷︷︸
homeostatic regulation and
boosting of immune memory
.
2.1 Numerical results
To perform numerical simulations, we set U = V := [0, 1], and we select the interval [0,T ] with
T = 120 as time domain. The parameters of the model are defined as κC,P := 1, μC,I := 0.5, θ := 1000,
μM := 1, βE,S := 1.
To replicate a scenario where a heterogeneous population of T cells is exposed to a population of
cancer cells that mainly express a given antigen, we consider an initial sample composed of: uniformly
distributed T cells; cancer cells that are mainly characterised by the antigenic expression u = 0.5.
The numerical results presented in Fig. 1 track the time-evolution of the two population densi-
ties, and reveal that the two cell populations undergo reciprocal selective sweeps. In more detail,
clonal-expansion leads to a rapid proliferation of those T cells that are targeted to the antigens mostly
expressed by cancer cells; in turn, the selective pressure exerted by T cells causes the selection of those
cancer cells that are able to evade immune predation. Immune competition pushes the monomorphic
cancer cell population to become, in succession, dimorphic, trimorphic, and then tetramorphic. T cells
follow a similar pattern of evolution, but with a shift corresponding to the time required for the T cells
to adapt to the antigenic distribution of cancer cells. These results suggest that our model can mimic
“chase-and-escape” dynamics involving the two cell populations.
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Figure 1. “Chase-and-escape" dynamics involving activated T cells and cancer cells without therapies.
Evolution of nC(t, u) (blue bars) and nI(t, v) (red bars) at different times from t = 0 (bottom line) to t = T (top
line). Clonal expansion leads to a rapid proliferation of those T cells that can effectively attack the antigens that
are mostly expressed by the cancer cell population. The selective pressure exerted by activated T-cells causes, in
turn, the selection of those cancer cells that are able to evade immune predation.
Next, we test the efficacy of different therapeutic protocols that rely on the periodic infusion of
P-agents and M-agents, separately and in combination. The results presented in the left and central
panels of Fig. 2 testify to the idea that P-agents (left panels) and M-agents (central panels) used
separately induce a temporary reduction in the total density of cancer cells, which is then followed by
a relapse.
On the other hand, the therapeutic protocols relying on the simultaneous infusion of sufficiently
high concentrations of P-agents and M-agents (right panels of Fig. 2) are the most effective, out of
those considered here, at pushing the cancer-cell population towards extinction and prevent a possible
relapse. This is due to the fact that, the simultaneous delivery of T-cell proliferation boosters and
boosters of immune memory, at sufficiently high doses, allow the total density of T cells to attain
higher values [5].
It is then natural to wonder what could be possible candidates for P-agents and M-agents in the
clinical setting. We propose that the cytokines IL-7 and IL-15 could play the roles of P-agents and
M-agents, since it has been experimentally demonstrated that increased levels of these interleukins in
vivo can effectively enhance antigen-independent proliferation and survival of antigen-specific CD4
and CD8 T cells [7].
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Figure 2. Cell dynamics with boosters of T-cell proliferation (P-agents) and boosters of immune mem-
ory (M-agents). We test three different instances of infusion: boosters of T-cell proliferation only, cP(t) :=
C f (t), cM(t) := 0 (left panels), boosters of T-cell memory only, cP(t) := 0, cM(t) := Cs f (t) (central panels) and
two types of immune boosters in combination, cP(t) := C/2 f (t), cM(t) := C/2 f (t) (right panels). We select a
periodic schedule with f (t) = sgn(sin(10π/Tt))+, and increasing values of the amount of therapeutical agent at
each injection: C = 4 (top panels, dotted lines), C = 6 (central panels, dashed lines) or C = 8 (bottom panels,
solid lines). Provided that the same value of the parameter C is used, the total delivered dose is the same in the
three cases. If the two types of immune boosters are used in combination, there exists certain doses that allow to
achieve the complete eradication of cancer cells (bottom right panel).
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